About this trial

This study is to identify rare, disease-causing mutations of several rare neutrophil dermatoses. To identify associations between NMID and variants in the genome next generation sequencing, mainly whole exome sequencing, will be used. In a second approach the expression level of already known inflammatory proteins in skin samples will be investigated.

Eligibility criteria

Qualifiers

written consent of the participating person

diagnosis of a disease in the NMID form group or proband of the control group

Disqualifiers

Missing informed consent if samples collected after 2014

no diagnosis of NMID

Missing informed consent

Trial design

Treatments tested in this trial

  • Analysis of samples
  • Analysis of samples
  • Analysis of samples
  • Analysis of samples

Treatment groups

3,370 Participants
are divided into 4 treatment groups

Locations

1
University Hospital Basel, Clinic of Dermatology4031, Basel Switzerland

Sponsors and collaborators

University Hospital, Basel, Switzerland

Lead sponsor